Trial · NCT06030804
Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery
NCT06030804, Not applicable, Recruiting, Peking University First Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery. Trials, record NCT06030804. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06030804
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery
- NCT number
- NCT06030804
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 4,532 participants, estimated
- Lead sponsor
- Peking University First Hospital
- Conditions
- Elderly, Cancer Surgery, Dexmedetomidine, Long-Term Survivors
- Interventions
- Dexmedetomidine, Placebo
- First posted
- 2023-09-11
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival after surgery | Up to 3 years after surgery of the last enrolled patient. | Time interval from index surgery to cancer recurrence/metastasis/progression or all-cause death, whichever comes first. |
| Secondary | Incidence of postoperative delirium. | During the first 4 postoperative days. | Delirium will be assessed with the 3D-Confusion Assessment Method (3D-CAM) or CAM for the Intensive Care Unit (CAM-ICU) twice daily during the first 4 postoperative days. |
| Secondary | Incidence of cognitive dysfunction at 6 months and 1 year postoperatively. | At 6 months and 1 year postoperatively. | Cognitive function will be assessed with the Telephone Montreal Cognitive Assessment (T-MoCA; scores range from 0 to 22, with higher score indicating better function) before surgery and at 6 months and 12 months after surgery. A T-MoCA score reduction of 1 standard deviation (SD) or more from baseline will be considered occurrence of cognitive dysfunction. |
| Other | Rate of intensive care unit (ICU) admission after surgery. | Up to 30 days after surgery. | Percentage of patients who required ICU admission within 30 days after surgery. |
| Other | Intensity of pain after surgery. | Two hours after surgery and during the first 4 postoperative days. | Intensity of pain will be assessed with the Numeric Rating Scale (NRS; an 11-point scale where 0=no pain and 10=the worst pain) twice daily during the first 4 postoperative days. |
| Other | Subjective sleep quality after surgery. | During the first 4 postoperative days. | Subjective sleep quality will be assessed with the Numeric Rating Scale (NRS; an 11-point scale where 0=the best sleep and 10=the worst sleep) once daily during the first 4 postoperative days. |
| Other | Length of stay in hospital after surgery. | Up to 30 days after surgery. | Length of stay in hospital after surgery. |
| Other | Incidence of postoperative complications within 30 days. | Up to 30 days after surgery. | Postoperative complications are defined as new-onset medical events other than delirium that are deemed harmful and require therapeutic intervention, that is grade II or higher on the Clavien-Dindo classification. |
| Other | Overall survival after surgery | Up to 3 years after surgery of the last enrolled patient. | Time interval from index surgery to all-cause death. |
| Other | Cancer-specific survival after surgery | Up to 3 years after surgery of the last enrolled patient. | Time interval from index surgery to cancer-specific death, with deaths from other causes being censored at the time of death. Cancer-specific death is defined as death fully attributable to the cancer for which the index surgery is performed and usually involves cancer recurrence/metastasis/progression after exclusion of other causes such as stroke and myocardial infarction. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers30
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06030804
GET https://conductscience.org/api/trials/v1/NCT06030804/papers?page=2